Dr. Stephen P. Spielberg is Dean, Dartmouth Medical School, Vice President for Health Affairs, Dartmouth College, and Professor of Pediatrics and of Pharmacology and Toxicology. He received an AB (Biology) from Princeton University, an MD and PhD (Pharmacology) from the University of Chicago, did a pediatric internship and residency at Children's Hospital, Boston, and a post-doctoral fellowship in human biochemical genetics at the National Institute of Child Health and Human Development. He then joined the faculty of Johns Hopkins University School of Medicine as Assistant Professor of Pediatrics and Pharmacology, moving to the University of Toronto, Hospital for Sick Children where he was Professor of Pediatrics and Pharmacology, Director of the Division of Clinical Pharmacology and Toxicology, and Director of the Centre for Drug Safety Research. After 15 years in academic medicine, he moved to Merck Research Laboratories as Executive Director, Exploratory Biochemical Toxicology and of Clinical and Regulatory Development in 1992, and subsequently to Johnson & Johnson in 1998 to become Vice President for Pediatric Drug Development. He was Chair of the Pediatric Task Force for PhRMA, represented the pharmaceutical industry on the FDA Pediatric Advisory Subcommittee and on pediatric legislative initiatives in the US and EU, and was the Rapporteur for the Pediatric ICH Initiative (ICH E-11) to harmonize pediatric drug development regulations among Europe, Japan, and the US.

He has served as Associate Editor of Drug Metabolism and Disposition, Section Editor for Therapeutics and Toxicology for Current Opinion in Pediatrics, and on the editorial boards of Clinical Pharmacology and Therapeutics, Pharmacoepidemiology and Drug Safety, Therapeutic Drug Monitoring, and Pediatric Alert. He is on the External Review Board of the Elizabeth Glaser Pediatric Research Network, the Board of Directors of the Foundation for the National Institutes of Health, Chairs the Pediatric Pharmacology Unit Advisory Board for the NICHD, is on the Council of the Convention of United States Pharmacopeia, and is President of the American Society for Clinical Pharmacology and Therapeutics (2006). His research interests include: mechanisms of idiosyncratic adverse drug reactions, human pharmacogenetics, and pediatric clinical pharmacology; he has published over 130 papers in these areas. He is the recipient of the Rawls-Palmer Award and Lectureship from the American Society of Clinical Pharmacology and Therapeutics (1992), the first recipient of the Werner Kalow Award in Pharmacogenetics and Drug Safety (1995), and the Williams B. Abrams Lectureship from FDA/ASCPT (2001).